Physicians: Dermatologists, Urologists and other physician reporters

  • Cancer Reporting Form Fillable (PDF) Instructions for Fillable Cancer Reporting Form (Word)
  • Patient Information Sheet
  • FAQs - Cancer Reporting for Dermatologists
  • SEER Summary Staging – 2018: Summary staging is the most basic way of categorizing how far a cancer has spread from its point of origin. Summary staging has also been called General Staging, California Staging, and SEER Staging. The 2018 version of Summary Stage applies to every anatomic site, including the lymphomas and leukemias. Summary staging uses all information available in the medical record; in other words, it is a combination of the most precise clinical and pathological documentation of the extent of disease. This is the staging system required by the Center for Disease Control's National Program of Cancer Registries (NPCR) as well as the North american association of Central Cancer Registries (NAACCR). Hospital registries approved by the Commission on Cancer use both the TNM Staging and the SEER Summary Staging. SEER Summary Staging (Melanomas)

Dermatologists 

Reportable Cases:

Determination of whether or not a given primary neoplasm is reportable is made by reference to the histology and behavior codes of the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3). The ICD-O-3 lists a preferred Histologic term along with synonyms, any of which applies. The following malignant and in situ neoplasms of the skin (C44) are reportable to MCR-ARC:

Code       Term 
8247/3    Merkel Cell Carcinoma  
8400/3    Sweat Gland Adenocarcinoma 
8410/3    Sebaceous Adenocarcinoma 
8720/2    Melanoma In Situ 
8720/3    Melanoma Malignant  
8721/3    Melanoma Nodular 
8730/3    Melanoma Amelanotic 
8742/2    Lentigo Maligna 
8742/3    Lentigo Maligna Melanoma 
8743/3    Melanoma Superficial Spreading 
8772/3    Melanoma Spindle Cell 
8800/3    Sarcoma
8810/3    Fibrosarcoma
8832/3    Dermatofibrosarcoma
8850/3    Liposarcoma
8890/3    Leiomyosarcoma
9140/3    Kaposi Sarcoma
9591/3    Non-Hodgkin Lymphoma
9650/3    Hodgkin Lymphoma
9680/3    Diffuse Large B-Cell Lymphoma
9700/3    Mycosis Fungoides
9709/3    Cutaneous T-Cell Lymphoma

Non-reportable Cases: 

Basal cell and squamous cell carcinoma are not reported to MCR-ARC.